MELISSA DOUBERLY: Open Payments
NPI 1942611744 · BRADENTON, FL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,487 in 54 payments from 15 companies in 2025. Trend: 2023 $899 · 2024 $1,331 · 2025 $1,487
Food & beverage: $1,403Education: $84
| Company | Payments | Amount |
|---|---|---|
| Janssen Biotech, Inc. | 14 | $543 |
| ABBVIE INC. | 16 | $335 |
| Madrigal Pharmaceuticals | 6 | $194 |
| GENZYME CORPORATION | 4 | $119 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $44 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 2 | $44 |
| Ardelyx, Inc. | 2 | $37 |
| QOL Medical, LLC | 1 | $35 |
| Regeneron Healthcare Solutions, Inc. | 1 | $26 |
| Novo Nordisk Inc | 1 | $23 |
Products named: TREMFYA, REZDIFFRA, RINVOQ, DUPIXENT, LINZESS, SKYRIZI, XIFAXAN, IBSRELA.
Industry payments across FL — which companies pay providers there.
